Little Green Pharma Ltd. · ASX:LGP
Little Green Pharma — Q1 FY2026 Earnings Presentation
20 slides from Little Green Pharma's earnings presentation, Nov 12, 2025
Slide 1: Quarterly & Appendix 4C Investor Presentation September 2025
September 2025 Quarterly & Appendix 4C ASX:LGP For personal use only Investor presentation SEPTEMBER 2025 The most trusted medicinal cannabis brand
Slide 2: Disclaimer
Disclaimer Disclaimer Not financial product advice This presentation contains summary information about Little Green Pharma Ltd (ACN 615 586 215) (“LGP”) For personal use only This document does not constitute financial product advice or take into account your investment objectives, taxation and its
Slide 3: Little Green Pharma
Little Green Pharma For personal use only 30t 5 BRANDS 37 PRODUCTS 4 FACILITIES PRODUCTION CAPACITY 11 13 SPONSORED 92 STAFF ACROSS 20+ STRAINS DISTRIBUTION TERRITORIES STUDIES / TRIALS 5 COUNTRIES GENETICS BANK
Slide 4: Revenue and cash receipts
Revenue and Little Green Pharma Ltd (ASX: LGP, “LGP” or the “Company”) is pleased to provide cash receipts its activities report and Appendix 4C for the quarter ending 30 September 2025 For personal use only • Revenue of $10.1 million (unaudited), up over 10% Cash receipts vs revenue ($000’s) on pri
Slide 5: Revenue by product category
Revenue by product category ($000’s) Revenue by 12,000 product category 10,000 8,000 For personal use only 6,000 4,000 Flower sales up nearly 15% overall, with over 25% growth in Australia. European 2,000 sales consistent with the prior quarter 0 FY25Q2 FY25Q3 FY25Q4 FY26Q1 FY26Q2 Flower Oil Vaporis
Slide 6: Revenue by segment
Revenue by segment ($000’s) Revenue by 12,000 segment 10,000 8,000 For personal use only 6,000 Overall European sales consistent with 4,000 prior quarter with an 80% increase in sales 2,000 to the UK offset by a 5% decrease in sales to Germany - FY25Q2 FY25Q3 FY25Q4 FY26Q1 FY26Q2 Australia Europe Au
Slide 7: Revenue by brand
Revenue by brand For personal use only Revenue by brand ($000’s) 12,000 White label sales down 5% with an 80% increase in UK sales and a September shipment to 10,000 Germany pushed into December quarter due to testing results delay 8,000 CherryCo sales up nearly 35% driven by a 20% increase in sales
Slide 8: Net cashflows from operations
• Cash costs between the quarters were consistent, with revenue up Net cashflows 10% but timing of cash receipts resulting in a 5% decrease between quarters from operations • German shipment scheduled for delivery in September with 50% payment on release pushed to early November due to third party t
Slide 9: EV, NTA, cash, debt and revenue
EV, NTA, cash, debt and revenue For personal use only EV, NTA, cash, debt & annualised revenue ($000’s) 100,000 100,000 Company’s net tangible assets continue to significantly exceed enterprise value 80,000 80,000 Minimal long-term debt of $3.0 million with over $5.0 million in unused credit facilit
Slide 10: European market update: Germany
European market Germany update $3.0 million in shipments delivered to Germany between July and September 2025 with additional shipment pushed into December quarter due to testing For personal use only delays [kg] Cannabis Flower Imports 45.000 Six new product permits granted for German market follow
Slide 11: European market update (cont.): Spain and France
European market Spain update (cont.) Launch of Royal Decree with product monograph expected in coming weeks For personal use only Narrow initial regulatory framework with prescribing and dispending limited to hospitals Flower excluded but extracts/oils permitted and no limits on indications LGP with
Slide 12: European market update (cont.): Poland, Denmark, UK
European market Poland update (cont.) Company submitted new dossier for LGP Denmark flower product to the Register of Medicinal Products (Rejestr Produktów Leczniczych), with For personal use only anticipated 12-month lead time from submission Denmark Fit-out of new room completed with Company plant
Slide 13: Health House update
Health House update For personal use only Multiple new customers onboarded to Health House following acquisition Successful launch of Victorian distribution and 3PL service in August 2025 Partnered with pharmacy technology provider to be first distributor to implement new cloud-based Ware S8 Premium
Slide 14: Automation and offshoring restructure
Automation and offshoring restructure For personal use only Automation and offshoring driven headcount reduction via Australian voluntary redundancy program expected to save up to $0.5 million annually Voluntary redundancies expected to cost $0.3 million with agreed deferred payment terms smoothing
Slide 15: TGA consultation update
TGA consultation update For personal use only First round of TGA consultation completed into Australian medicinal cannabis quality and safety with over 750 submissions received from industry sponsors, prescribers, associations and patients Breadth of anticipated regulatory reforms set to create larg
Slide 16: Gartner hype cycle
LGP’s share price is strongly correlated to the US cannabis Gartner hype cycle market as represented by the MSOS Index The MSOS Index shows characteristics of the Gartner Hype Cycle which includes: For personal use only An innovation trigger or new Early growth phase Shake-out phase Growth phase Mar
Slide 17: Slope of Enlightenment?
Slope of Enlightenment? Early signs that the MSOS Index may have passed through the Trough of For personal use only Disillusionment and moved towards the Slope of Enlightenment Total Return (%) +150.00% Market appears to have more confidence that +125.00% President Trump will reschedule cannabis in
Slide 18: Corporate overview
Corporate overview For personal use only Capital structure Shareholder structure Current share price1 $0.130 Shares outstanding1 ~306 million Options and performance rights on Issue2 ~32 million 24% Market capitalisation (undiluted) ~$40 million 37% Cash reserves (30 September 2025) ~$2.3 million 23
Slide 19: Delivering on strategy
THE NEXT 6 MONTHS Delivering on strategy For personal use only Opening of French and Spanish markets, with LGP targeting first registered medicinal cannabis product in France Continued supply into other EU growth markets Development of LGP’s Danish facility into European cannabis processing hub from
Slide 20: Q&A
For personal use only Q&A Paul Long, Managing Director A world of difference investor.littlegreenpharma.com
Little Green Pharma — Q1 FY2026 Earnings Presentation on 6ix